yingweiwo

Imatinib (STI571; Gleevec; Glivec)

Alias: CGP-57148B; ST-1571, CGP057148B; CGP 57148; CGP57148; CGP-57148; CGP57148B; CGP 57148B; STI571; STI 571; Imatinib; US brand name: Gleevec; Foreign brand name: Glivec
Cat No.:V0573 Purity: ≥98%
Imatinib (formerly STI-571, trade name Gleevec and Glivec) is an orally bioavailable multi-targeted kinase inhibitor with potential anticancer activity.
Imatinib (STI571; Gleevec; Glivec)
Imatinib (STI571; Gleevec; Glivec) Chemical Structure CAS No.: 152459-95-5
Product category: PDGFR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
250mg
500mg
1g
2g
5g
10g
Other Sizes

Other Forms of Imatinib (STI571; Gleevec; Glivec):

  • Imatinib-d8 mesylate (STI571-d8 (mesylate); CGP-57148B-d8 (mesylate))
  • Imatinib D8
  • N-Desmethyl imatinib-d4 (N-Desmethyl imatinib d8-d4; Norimatinib-d4; Imatinib metabolite N-Desmethyl imatinib-d4)
  • Imatinib D4
  • Imatinib-d3 hydrochloride (STI571-d3 (hydrochloride); CGP-57148B-d3 (hydrochloride))
  • N-Desmethyl imatinib mesylate (Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate)
  • Imatinib Mesylate (STI571; Gleevec; Glivec)
  • Imatinib metabolite N-Desmethyl Imatinib
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Imatinib (formerly STI-571, trade name Gleevec and Glivec) is an orally bioavailable multi-targeted kinase inhibitor with potential anticancer activity. With IC50 values of 0.6 μM, 0.1 μM, and 0.1 μM in cell-free and/or cell-based assays, respectively, it inhibits v-Abl, c-Kit, and PDGFR. In order to inhibit ATP binding, phosphorylation, and the subsequent activation of growth receptors and their downstream signal transduction pathways, imatinib binds to the intracellular domain of tyrosine kinases (TK). Tyrosine kinases carried by the bcr-abl oncogene, along with receptor TKs carried by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes, are inhibited by imatinib.

Biological Activity I Assay Protocols (From Reference)
Targets
PDGFR (IC50 = 100 nM); c-Kit (IC50 = 100 nM); v-Abl (IC50 = 600 nM)
ln Vitro
Imatinib (STI571) inhibits c-Kit autophosphorylation, MAPK activation, and Akt activation without changing the overall amounts of c-kit, MAPK, or Akt proteins. Approximately 100 nM is the concentration at which these effects are 50% inhibited[1].
Imatinib (STI571) has a very high in vitro IC50 of 25 nM against the kinase Bcr-Abl, which causes chronic myeloid leukemia. Additionally, Kit (in vitro IC50: 410 nM) and PDGFR (in vitro IC50: 380 nM) are effectively inhibited by imatinib[2].
Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit, and it also inhibits the native PDGFβ receptor, Bcr/Abl, v-Abl, Tel/Abl, and c-Kit. However, it does not inhibit the EGFR, c-Fms, Flt3, Src family kinases, or numerous other tyrosine kinases. Imatinib has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2[4]. However, it inhibits the tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case.
Imatinib (STI571), a multi-target inhibitor, has IC50s of 32.4 and 32.8 μM for v-Abl, c-Kit, and BON-1 and H727 cells after 48 hours of exposure[6].
ln Vivo
Tumor growth inhibition is 59.437% in the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, significantly higher than in the liposome negative control group (2.759%) and the Imatinib (STI571) multi-target inhibitor of v-Abl, c-Kit and group (11.071%) groups. When compared to the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163), telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158)[7]. Imatinib (25 mg/kg/day, p.o.) inhibits the growth of endometriotic tissue and decreases the quantity of ovarian follicles in a rat model. Through its inhibitory effects on angiogenesis and cell proliferation, imatinib effectively treats experimental endometriosis[8].
Enzyme Assay
Rabbit antiserum is used to immunoprecipitate the PDGF receptor from extracts of BALB/c 3T3 cells, which is then left on ice for two hours. Antigen-antibody complexes are gathered using protein A-Sepharose beads. TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and kinase buffer (20 mM Tris, pH 7.5, 10 mM MgCl2) are the three solutions used to wash the immunoprecipitates twice. A variety of drug concentrations are added to the reaction mixture after PDGF (50 ng/mL) stimulation for 10 minutes at 4 °C. Incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C is used to measure PDGF receptor kinase activity. SDS-PAGE is used to separate immune complexes on 7.5% gels.
Cell Assay
In triplicate, BON-1 and NCI-H727 cells are seeded into flat-bottomed 96-well plates, and they are then left to adhere overnight in either RPMI 1640 complete medium or 10% fetal bovine serum-supplemented DMEM. The medium is then changed to either serum-free medium (which serves as a negative control) or serum-free medium that contains serial dilutions of imatinib. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay is used to count the number of metabolically active cells after 48 hours (control cultures do not reach confluence). The absorbance is then measured at 540 nm using a Packard Spectra microplate reader. Inhibition rate = (1 − a / b) × 100% is the formula used to calculate growth inhibition, where a and b represent the absorbance values of the treated and control groups, respectively.
Animal Protocol
Mice: The 40 SCID mice with tumors are split into four groups at random, with 10 mice in each group: the PS-ASODN group (5 μM, intratumor injection once daily, 0.2 mL per mouse), the Imatinib group (0.1 mg/g body weight), the liposome negative control group (0.01 mL/g), and the saline group (0.01 mL/g). From the seventh to the twenty-eighth day following implantation, the mice in each group are given the appropriate treatment by intratumor injection once a day. The mice are killed after 28 days, and an electronic scale and a vernier caliper are used to measure the tumor's weight as well as its longest and shortest diameters. Tumor growth inhibition is computed.
Rats: It uses adult female Wistar-Albino rats weighing between 220 and 240 g. To assess if endometriosis has occurred, the rats have a second laparotomy twenty-one days following the first surgical procedure. Anastrozole (0.004 mg/day, p.o.), Imatinib (25 mg/kg/day), or normal saline (0.1 mL, i.p.) are the three groups of rats that are randomly assigned to receive treatment for 14 days after having visually confirmed endometriotic implants in 24 rats.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Imatinib is well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose. Mean absolute bioavailability is 98%. Mean imatinib AUC increases proportionally with increasing doses ranging from 25 mg to 1,000 mg. There is no significant change in the pharmacokinetics of imatinib on repeated dosing, and accumulation is 1.5- to 2.5-fold at a steady state when Gleevec is dosed once daily.
Imatinib elimination is predominately in the feces, mostly as metabolites. Based on the recovery of compound(s) after an oral 14C-labeled dose of imatinib, approximately 81% of the dose was eliminated within 7 days, in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.
Population pharmacokinetics in adult CML patients estimated the steady-state volume of distribution of imatinib to be 295.0 ± 62.5 L.At a dose of 340 mg/m2, the volume of distribution of imatinib in pediatric patients was calculated to be 167 ± 84 L.
Typically, clearance of imatinib in a 50-year-old patient weighing 50 kg is expected to be 8 L/h, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/h. The inter-patient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment-related toxicities.
Metabolism / Metabolites
CYP3A4 is the major enzyme responsible for the metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to the parent imatinib.
Imatinib has known human metabolites that include N-desmethylimatinib.
Biological Half-Life
Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-desmethyl derivative (CGP74588), are approximately 18 and 40 hours, respectively.
Toxicity/Toxicokinetics
Hepatotoxicity
Imatinib therapy is associated with three forms of acute liver injury: transient and usually asymptomatic elevations in serum enzymes during treatment, clinically apparent acute hepatitis, and reactivation of an underlying chronic hepatitis B.
Elevations in serum aminotransferase levels are common during imatinib therapy, but ALT levels above 5 times the upper limit of the normal range occur in only 2% to 4% of patients treated for 6 months or more. In addition, mild elevations in serum bilirubin can occur. These abnormalities are usually mild, asymptomatic, and resolve despite continuing therapy. Nevertheless, dose adjustment or temporary discontinuation and restarting at a lower dose may be needed and is recommended if levels are markedly elevated (ALT or AST persistently >5 times ULN or bilirubin >3 times ULN).
In addition, imatinib has been linked to rare instances of clinically apparent acute liver injury with jaundice. The time to onset has varied from 6 days to as long as several years after starting treatment, the usual latency being 2 to 6 months (Cases 1 and 2). The pattern of serum enzyme elevations is typically hepatocellular, although cholestatic and mixed forms of hepatitis have also been reported. The injury can be severe and instances of acute liver failure and death have been reported as well as severe hepatitis resulting in a posthepatitic cirrhosis. Immunoallergic features (rash, fever and eosinophilia) are not common, but some patients develop low levels of autoantibodies and instances of chronic hepatitis on long term imatinib have been reported. More importantly, many instances of an apparent clinical response to prednisone therapy have been described. Recurrence of injury is common with reexposure, but concurrent prednisone therapy may blunt or prevent the recurrence of liver injury and, in some instances, has allowed for continued, long term therapy despite a previous bout of clinically apparent liver injury on imatinib.
Finally, there have been several instances of reactivation of chronic hepatitis B during imatinib therapy in patients with inactive hepatitis B or the HBsAg carrier state (Case 3). The clinical presentation is generally with an acute hepatitis like syndrome with marked elevations in serum ALT and minimal changes in alkaline phosphatase levels. Typically, hepatitis B virus (HBV) DNA is present in serum in increasing levels early in the course of reactivation which rapidly falls to pretreatment levels with recovery. Patients may also test positive for IgM antibody to hepatitis B core antigen (IgM anti-HBc). Reactivation of hepatitis B due to imatinib can be severe and fatal instances have been reported.
Likelihood score: B (likely cause of clinically apparent liver injury as well as reactivation of hepatitis B).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Limited information indicates that maternal doses of imatinib up to 400 mg daily produce low levels of the drug and its active metabolite in milk. Although a few breastfed infants apparently experienced no adverse effects during maternal use of imatinib, no long-term data are available. Until more data are available, imatinib should be used only with careful monitoring during breastfeeding. National Comprehensive Cancer Network guidelines, the manufacturer and some authors recommend that breastfeeding be discontinued during imatinib therapy and for 1 month after therapy.
◉ Effects in Breastfed Infants
A woman receiving oral imatinib 400 mg daily for chronic myeloid leukemia breastfed her infant. No adverse effects were noted in the infant during the first 2 months of nursing.
One woman with chronic myelogenous leukemia received imatinib 400 mg daily throughout pregnancy and during breastfeeding (extent not stated) for nearly 6 months postpartum. Her infant reportedly grew and developed normally.
A woman with chronic myeloid leukemia received imatinib 400 mg daily starting at week 8 of pregnancy and continuing throughout 8 months of breastfeeding (extent not stated). The infant was healthy, but an atrial septal defect was repaired at 30 months of age. It was thought to be unrelated to imatinib therapy.
A pregnant woman with Philadelphia chromosome-positive chronic myelogenous leukemia was started on imatinib 400 mg daily during pregnancy. After delivery, her preterm infant was fed colostrum until the middle of the fifth day postpartum when exclusive formula feeding was instituted. The infant was treated for apnea of prematurity and discharged on day 25 of life. No adverse effects on growth or development were noted during the first year of life.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
At clinically relevant concentrations of imatinib, binding to plasma proteins in in vitro experiments is approximately 95%, mostly to albumin and α1-acid glycoprotein.
References

[1]. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.

[2]. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

[3]. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.

[4]. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8.

[5]. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630.

[6]. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40.

[7]. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7.

[8]. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63.

[9]. Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12.

Additional Infomation
Pharmacodynamics
Imatinib is a 2-phenylaminopyrimidine derivative neoplastic agent that belongs to the class of tyrosine kinase inhibitors. Although imatinib inhibits a number of tyrosine kinases, it is quite selective toward the BCR-ABL fusion protein that is present in various cancers. BCR-ABL pathway controls many downstream pathways that are heavily implicated in neoplastic growth such as the Ras/MapK pathway (cellular proliferation), Src/Pax/Fak/Rac pathway (cellular motility), and PI/PI3K/AKT/BCL-2 pathway (apoptosis pathway). Therefore, the BCR-ABL pathway is an attractive target for cancer treatment. Although normal cells also depend on these pathways for growth, these cells tend to have redundant tyrosine kinases to continually function in spite of ABL inhibition from imatinib. Cancer cells, on the other hand, can have a dependence on BCR-ABL, thus more heavily impacted by imatinib.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C29H31N7O
Molecular Weight
493.6
Exact Mass
493.259
Elemental Analysis
C, 70.56; H, 6.33; N, 19.86; O, 3.24
CAS #
152459-95-5
Related CAS #
Imatinib-d8;1092942-82-9;Imatinib-d4;1134803-16-9;Imatinib-d3 hydrochloride;1134803-18-1;Imatinib Mesylate;220127-57-1;N-Desmethyl imatinib;404844-02-6
PubChem CID
5291
Appearance
White to off-white to brownish or yellowish tinged crystalline powder
Density
1.3±0.1 g/cm3
Boiling Point
451°C
Melting Point
113°C
Flash Point
196°C
Vapour Pressure
6.03E-24mmHg at 25°C
Index of Refraction
1.672
LogP
2.48
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
7
Heavy Atom Count
37
Complexity
706
Defined Atom Stereocenter Count
0
SMILES
O=C(C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])N([H])C1C([H])=C([H])C(C([H])([H])[H])=C(C=1[H])N([H])C1=NC([H])=C([H])C(C2=C([H])N=C([H])C([H])=C2[H])=N1
InChi Key
KTUFNOKKBVMGRW-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
Chemical Name
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Synonyms
CGP-57148B; ST-1571, CGP057148B; CGP 57148; CGP57148; CGP-57148; CGP57148B; CGP 57148B; STI571; STI 571; Imatinib; US brand name: Gleevec; Foreign brand name: Glivec
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~4 mg/mL (~8.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 2% DMSO+30% PEG 300+2% Tween 80+ddH2O: 2mg/mL

Solubility in Formulation 5: 11 mg/mL (22.29 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0259 mL 10.1297 mL 20.2593 mL
5 mM 0.4052 mL 2.0259 mL 4.0519 mL
10 mM 0.2026 mL 1.0130 mL 2.0259 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
CTID: NCT06682169
Phase: Phase 3    Status: Recruiting
Date: 2024-11-26
Asciminib Roll-over Study
CTID: NCT04877522
Phase: Phase 4    Status: Recruiting
Date: 2024-11-25
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
CTID: NCT06090669
Phase: Phase 1    Status: Recruiting
Date: 2024-11-25
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
CTID: NCT00044304
Phase: Phase 2    Status: Recruiting
Date: 2024-11-19
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
CTID: NCT06692491
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-18
View More

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
CTID: NCT06051409
Phase: Phase 3    Status: Recruiting
Date: 2024-11-07


A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
CTID: NCT03589326
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-31
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
CTID: NCT03722420
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-28
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
CTID: NCT06646978
Phase:    Status: Enrolling by invitation
Date: 2024-10-17
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
CTID: NCT02881086
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-10
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
CTID: NCT06628739
Phase:    Status: Completed
Date: 2024-10-08
Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis
CTID: NCT06626984
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2024-10-04
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
CTID: NCT06061094
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Trial of Imatinib for Hospitalized Adults With COVID-19
CTID: NCT04394416
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-08-27
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
CTID: NCT04598009
Phase: Phase 2    Status: Recruiting
Date: 2024-08-22
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
CTID: NCT02326311
Phase: Phase 3    Status: Completed
Date: 2024-08-13
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
CTID: NCT05245968
Phase: Phase 1    Status: Recruiting
Date: 2024-08-07
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
CTID: NCT05152472
Phase: Phase 2    Status: Recruiting
Date: 2024-07-25
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
CTID: NCT04307576
Phase: Phase 3    Status: Recruiting
Date: 2024-07-12
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
CTID: NCT02735707
Phase: Phase 3    Status: Recruiting
Date: 2024-07-12
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
CTID: NCT03654768
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-08
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
CTID: NCT03469011
Phase: Phase 1    Status: Recruiting
Date: 2024-06-14
Precision Cancer Therapy in Rare Cancers
CTID: NCT06119789
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-05-29
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
CTID: NCT03578367
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
CTID: NCT04971226
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-05-03
ALL Adult Consortium Trial: Adult ALL Trial
CTID: NCT00476190
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-04-17
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
CTID: NCT04070443
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-04-08
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
CTID: NCT04838041
Phase: Phase 2    Status: Recruiting
Date: 2024-04-03
Imatinib TDM in GIST
CTID: NCT05493215
Phase: Phase 2    Status: Recruiting
Date: 2024-04-01
Ma-Spore ALL 2020 Study
CTID: NCT06336395
Phase: Phase 2    Status: Recruiting
Date: 2024-03-28
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
CTID: NCT05143840
Phase: Phase 2    Status: Recruiting
Date: 2024-03-26
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
CTID: NCT02081378
Phase: Phase 1    Status: Completed
Date: 2024-03-18
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
CTID: NCT05816785
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-03-08
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
CTID: NCT03878524
Phase: Phase 1    Status: Terminated
Date: 2024-03-04
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
CTID: NCT04722848
Phase: Phase 3    Status: Recruiting
Date: 2024-02-07
Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
CTID: NCT06219733
Phase: Phase 2    Status: Recruiting
Date: 2024-01-23
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
CTID: NCT01541709
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-01-02
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
CTID: NCT06175702
Phase:    Status: Not yet recruiting
Date: 2023-12-19
KISS Study: Kinase Inhibition With Sprycel Start up
CTID: NCT03193281
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-11-29
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
CTID: NCT02352558
Phase: Phase 1    Status: Completed
Date: 2023-11-14
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
CTID: NCT02413736
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-11-09
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
CTID: NCT05286528
Phase:    Status: Completed
Date: 2023-10-27
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
CTID: NCT03891901
Phase: Phase 2    Status: Completed
Date: 2023-10-23
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
CTID: NCT05413915
Phase: Phase 3    Status: Recruiting
Date: 2023-10-23
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
CTID: NCT04330690
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-10-13
The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases
CTID: NCT06038552
Phase:    Status: Completed
Date: 2023-09-15
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
CTID: NCT05009927
Phase: Phase 2    Status: Recruiting
Date: 2023-09-01
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
CTID: NCT03112603
Phase: Phase 3    Status: Completed
Date: 2023-07-18
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
CTID: NCT02365441
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-07-07
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
CTID: NCT01593254
Phase: Phase 2    Status: Completed
Date: 2023-06-22
Exploring the Molecular Mechanism Based on KIT Mutation
CTID: NCT05895942
Phase:    Status: Recruiting
Date: 2023-06-09
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children
CTID: NCT00287105
Phase: Phase 2    Status: Completed
Date: 2023-05-24
Frontline Asciminib Combination in Chronic Phase CML
CTID: NCT03906292
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-05-10
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
CTID: NCT04138381
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2023-03-27
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
CTID: NCT02269267
Phase: Phase 2    Status: Completed
Date: 2023-03-03
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
CTID: NCT05722795
Phase: N/A    Status: Not yet recruiting
Date: 2023-02-10
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
CTID: NCT00812240
Phase: Phase 3    Status: Terminated
Date: 2023-02-01
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
CTID: NCT03885830
Phase:    Status: Completed
Date: 2023-01-11
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
CTID: NCT01475110
Phase:    Status: Completed
Date: 2022-10-25
Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study
CTID: NCT01025505
Phase: Phase 2    Status: Completed
Date: 2022-10-12
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
CTID: NCT01319981
Phase: Phase 2    Status: Completed
Date: 2022-09-27
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
CTID: NCT03170180
Phase: Phase 2    Status: Completed
Date: 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
CTID: NCT02461849
Phase: Phase 2    Status: Unknown status
Date: 2022-06-15
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
CTID: NCT05367765
Phase: Phase 4    Status: Not yet recruiting
Date: 2022-05-10
SOLIDARITY Finland Plus Long-COVID
CTID: NCT05220280
Phase: Phase 4    Status: Recruiting
Date: 2022-05-03
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
CTID: NCT02462538
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2022-03-03
Effect of Imatinib in Advance Liver Fibrosis Patients
CTID: NCT05224128
Phase: Phase 1/Phase 2    Status: Unknown status
Date: 2022-02-04
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
CTID: NCT02602314
Phase: Phase 4    Status: Unknown status
Date: 2022-01-20
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
CTID: NCT01491763
Phase: Phase 4    Status: Unknown status
Date: 2022-01-19
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
CTID: NCT04933669
Phase: Phase 2    Status: Recruiting
Date: 2021-10-12
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
CTID: NCT05071482
Phase: Phase 4    Status: Recruiting
Date: 2021-10-08
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19
CTID: NCT04346147
Phase: Phase 2    Status: Unknown status
Date: 2021-08-03
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
CTID: NCT00171223
Phase: Phase 2    Status: Completed
Date: 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
CTID: NCT00171249
Phase: Phase 2    Status: Completed
Date: 2021-07-22
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
CTID: NCT00613171
Phase: Phase 2    Status: Completed
Date: 2021-07-07
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
CTID: NCT01275222
Phase: Phase 1/Phase 2    Status: Completed
Date: 2021-06-25
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
CTID: NCT01392469
Phase: Phase 3    Status: Completed
Date: 2021-06-21
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
CTID: NCT02130557
Phase: Phase 3    Status: Completed
Date: 2021-05-18
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints
CTID: NCT01216085
Phase: Phase 2    Status: Completed
Date: 2021-03-10
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
CTID: NCT03454503
Phase:    Status: Completed
Date: 2021-02-23
Study in Adult Ph-positive ALL
CTID: NCT04688983
Phase: Phase 2    Status: Not yet recruiting
Date: 2020-12-30
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
CTID: NCT01468688
Phase: Phase 1    Status: Completed
Date: 2020-12-21
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
CTID: NCT00471497
Phase: Phase 3    Status: Completed
Date: 2020-11-18
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
CTID: NCT04578847
Phase: Phase 2    Status: Active, not recruiting
Date: 2020-10-08
Imatinib in Acute Ischaemic Stroke
CTID: NCT03639922
Phase: Phase 3    Status: Unknown status
Date: 2020-09-16
PLATFORM Study of Precision Medicine for Rare Tumors
CTID: NCT04423185
Phase: Phase 2    Status: Unknown status
Date: 2020-08-04
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
CTID: NCT00390156
Phase: Phase 1    Status: Completed
Date: 2020-07-28
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
CTID: NCT00760981
Phase: Phase 1    Status: Completed
Date: 2020-04-15
STI571 ProspectIve RandomIzed Trial: SPIRIT
CTID: NCT00219739
Phase: Phase 3    Status: Completed
Date: 2020-04-13
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
CTID: NCT02638428
Phase: Phase 2    Status: Unknown status
Date: 2020-03-19
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
CTID: NCT02495519
Phase: Phase 2    Status: Completed
Date: 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
CTID: NCT01151852
Phase: Phase 3    Status: Completed
Date: 2020-01-14
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
CTID: NCT03844360
Phase: Phase 4    Status: Unknown status
Date: 2020-01-10
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
CTID: NCT02174445
Phase: Phase 3    Status: Terminated
Date: 2019-12-02
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
CTID: NCT02611492
Phase: Phase 3    Status: Recruiting
Date: 2019-10-21
Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy
CTID: NCT02685046
Phase: Phase 2    Status: Terminated
Date: 2019-10-14
Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
CTID: NCT03343600
Phase: Phase 2    Status: Terminated
Date: 2019-09-11
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
CTID: NCT02272777
Phase: Phase 3    Status: Completed
Date: 2019-08-19
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
CTID: NCT00632255
Phase:    Status: Completed
Date: 2019-07-08
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
CTID: NCT03862768
Phase: N/A    Status: Unknown status
Date: 2019-03-05
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
CTID: NCT00574873
Phase: Phase 3    Status: Completed
Date: 2019-01-08
Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
CTID: NCT03697668
Phase: Phase 2    Status: Unknown status
Date: 2018-10-05
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
CTID: NCT00415857
Phase: Phase 2    Status: Terminated
Date: 2018-08-21
A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury
CTID: NCT03328117
Phase: Phase 1    Status: Completed
Date: 2018-07-13
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
CTID: NCT01568645
Phase: Phase 1    Status: Withdrawn
Date: 2018-07-05
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
CTID: NCT02204722
Phase: Phase 4    Status: Terminated
Date: 2018-06-15
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
CTID: NCT03515018
Phase: Phase 3    Status: Unknown status
Date: 2018-05-22
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
CTID: NCT01460693
Phase: Phase 3    Status: Completed
Date: 2018-04-24
Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study
CTID: NCT02363361
Phase: Phase 2    Status: Unknown status
Date: 2018-03-07
To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.
CTID: NCT03424876
Phase:    Status: Unknown status
Date: 2018-03-01
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
CTID: NCT03381053
Phase:    Status: Unknown status
Date: 2017-12-21
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
CTID: NCT03228303
PhaseEarly Phase 1    Status: Unknown status
Date: 2017-10-10
Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
CTID: NCT00852566
Phase: Phase 2    Status: Completed
Date: 2017-09-25
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
CTID: NCT00079313
Phase: Phase 2    Status: Completed
Date: 2017-07-02
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
CTID: NCT01316458
Phase: Phase 2    Status: Completed
Date: 2017-06-01
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
CTID: NCT01804985
Phase: Phase 2    Status: Unknown status
Date: 2017-05-04
Study to Evaluate Imatinib in Desmoid Tumors
CTID: NCT01137916
Phase: Phase 2    Status: Completed
Date: 2017-05-03
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
CTID: NCT00154336
Phase: Phase 2    Status: Completed
Date: 2017-04-25
Treatment of Older Adults With Acute Lymphoblastic Leukemia
CTID: NCT00973752
Phase: Phase 2    Status: Completed
Date: 2017-03-30
Efficacy and Safety of Imatinib in Chordoma
CTID: NCT00150072
Phase: Phase 2    Status: Completed
Date: 2017-02-23
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
CTID: NCT00481247
Phase: Phase 3    Status: Completed
Date: 2017-02-15
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
CTID: NCT00585221
Phase: Phase 2    Status: Terminated
Date: 2017-02-10
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
CTID: NCT00424515
Phase: Phase 2    Status: Completed
Date: 2016-12-08
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
CTID: NCT02977312
Phase:    Status: Completed
Date: 2016-11-30
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
CTID: NCT00760877
Phase: Phase 3    Status: Completed
Date: 2016-11-08
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
CTID: NCT01188278
Phase:    Status: Completed
Date: 2016-09-30
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
CTID: NCT02894645
Phase: Phase 4    Status: Unknown status
Date: 2016-09-30
Population Pharmacokinetics of Imatinib in CML Patients in Iran
CTID: NCT02146846
Phase:    Status: Terminated
Date: 2016-09-07
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
CTID: NCT02013089
Phase: N/A    Status: Unknown status
Date: 2016-08-30
A Study of Nilotinib Versus Imatinib in GIST Patients
CTID: NCT00785785
Phase: Phase 3    Status: Completed
Date: 2016-06-16
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
CTID: NCT00193180
Phase: Phase 2    Status: Completed
Date: 2016-05-27
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
CTID: NCT01275196
Phase: Phase 3    Status: Completed
Date: 2016-04-08
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
CTID: NCT00420043
Phase: Phase 1    Status: Completed
Date: 2016-04-05
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
CTID: NCT00422825
Phase: Phase 1    Status: Completed
Date: 2016-04-05
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
CTID: NCT01511289
Phase: Phase 3    Status: Completed
Date: 2016-02-24
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
CTID: NCT00982488
Phase: Phase 2    Status: Completed
Date: 2016-01-22
Imatinib in Adult Patients With Metastatic Ocular Melanoma
CTID: NCT00421317
Phase: Phase 2    Status: Terminated
Date: 2016-01-06
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
CTID: NCT00802841
Phase: Phase 3    Status: Completed
Date: 2015-11-16
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
CTID: NCT02576080
Phase: Phase 3    Status: Unknown status
Date: 2015-10-15
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
CTID: NCT01117987
Phase: Phase 3 Status:
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH).
CTID: null
Phase: Phase 2, Phase 3    Status: Trial now transitioned, Ongoing
Date: 2022-02-21
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
CTID: null
Phase: Phase 3    Status: Trial now transitioned, Ongoing
Date: 2021-08-10
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
CTID: null
Phase: Phase 3    Status: Completed, Trial now transitioned, Ongoing
Date: 2021-08-10
GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in patients with locally advanced/metastatic Gastrointestinal Stromal Tumors (GISTs)
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2021-07-08
ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
CTID: null
Phase: Phase 3    Status: Trial now transitioned, GB - no longer in EU/EEA, Ongoing
Date: 2020-05-15
WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19)
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2020-04-29
A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2020-04-17
Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF)
CTID: null
Phase: Phase 2    Status: Completed
Date: e.querySelector("font strong").innerText = 'View More' } else if(up_display === 'none' || up_display ==

Biological Data
  • Imatinib (STI571)

  • Imatinib (STI571)
Contact Us